Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 9/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4589751 | 0.87 | KDM4E (0.51) | METTL3EGLN1L3MBTL1NAMPTMAP3K5 | |
| SCHEMBL22529159 | 0.83 | METTL3 (0.51) | METTL3L3MBTL1NAMPTMAP3K5 | |
| SCHEMBL8867560 | 0.82 | ALDH1A1 (0.48) | METTL3NAMPTMAP3K5 | |
| SCHEMBL22499267 | 0.82 | METTL3 (0.50) | METTL3L3MBTL1NAMPTMAP3K5 | |
| SCHEMBL12393079 | 0.80 | PTGS1 (0.44) | EGLN1NAMPTPTGS1PTGS2 | |
| SCHEMBL8866334 | 0.80 | RAB9A (0.45) | METTL3 | |
| SCHEMBL22527624 | 0.80 | METTL3 (0.48) | METTL3L3MBTL1NAMPTMAP3K5 | |
| SCHEMBL8866825 | 0.78 | ALDH1A1 (0.50) | METTL3L3MBTL1NAMPTMAP3K5GRM2 | |
| SCHEMBL22499329 | 0.77 | METTL3 (0.46) | METTL3L3MBTL1NAMPTMAP3K5 | |
| SCHEMBL8867188 | 0.75 | SUV39H2 (0.44) | METTL3NAMPTMAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207650-A1 | Chemical Compounds 636 | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207650-A1 | Chemical Compounds 636 | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207650-A1 | Chemical Compounds 636 | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| WO-2008084240-A1 | CHEMICAL COMPOUNDS 636 : PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207650-A1 | Chemical Compounds 636 | PDE4A, PDE3B, PDE3A | METTL3 4378/4885EGLN1 2058/4885L3MBTL1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.